These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 38929666)

  • 21. [Expression of PD-1/PD-L1 in triple-negative breast carcinoma and its significance].
    Zhang W; Xu GX; Li JJ; Liu X; Chen YJ; Zhang F
    Zhonghua Bing Li Xue Za Zhi; 2017 Jan; 46(1):20-24. PubMed ID: 28072971
    [No Abstract]   [Full Text] [Related]  

  • 22. Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer.
    Li M; Li A; Zhou S; Xu Y; Xiao Y; Bi R; Yang W
    BMC Cancer; 2018 Jan; 18(1):4. PubMed ID: 29291717
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Association of Tumor-Infiltrating Lymphocytes and Programmed Cell Death 1 Expression with the Incidence of Distant Metastasis in Triple-Negative Breast Cancer Subjects in Sanglah General Hospital, Bali, Indonesia.
    Sudarsa IW; Gunawan IPA; Manuaba IBTW
    Case Rep Oncol; 2021; 14(1):347-351. PubMed ID: 33776728
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The prognostic value of a combined immune score in tumor and immune cells assessed by immunohistochemistry in triple-negative breast cancer.
    Choi JE; Lee JS; Jin MS; Nikas IP; Kim K; Yang S; Park SY; Koh J; Yang S; Im SA; Ryu HS
    Breast Cancer Res; 2023 Nov; 25(1):134. PubMed ID: 37924153
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of PD-1/PD-L1 inhibitors in triple-negative breast cancer: a systematic review and meta-analysis.
    Zhang M; Song J; Yang H; Jin F; Zheng A
    Acta Oncol; 2022 Sep; 61(9):1105-1115. PubMed ID: 35939538
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Investigating the clinical significance of EGFR expression using machine learning in a series of Iraqi patients with triple-negative breast cancer.
    Salman G; Aldujaily E; Jabardi M; Qassid OL
    J Med Life; 2022 Aug; 15(8):967-978. PubMed ID: 36188649
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Programmed death-ligand 1 (PD-L1) expression predicts response to neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis.
    Azim HA; Shohdy KS; Elghazawy H; Salib MM; Almeldin D; Kassem L
    Biomarkers; 2022 Dec; 27(8):764-772. PubMed ID: 35980714
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic Role and Clinical Significance of Tumor-Infiltrating Lymphocyte (TIL) and Programmed Death Ligand 1 (PD-L1) Expression in Triple-Negative Breast Cancer (TNBC): A Systematic Review and Meta-Analysis Study.
    Lotfinejad P; Asghari Jafarabadi M; Abdoli Shadbad M; Kazemi T; Pashazadeh F; Sandoghchian Shotorbani S; Jadidi Niaragh F; Baghbanzadeh A; Vahed N; Silvestris N; Baradaran B
    Diagnostics (Basel); 2020 Sep; 10(9):. PubMed ID: 32957579
    [TBL] [Abstract][Full Text] [Related]  

  • 29. STAT3 and PD-L1 are negatively correlated with ATM and have impact on the prognosis of triple-negative breast cancer patients with low ATM expression.
    Song YM; Qian XL; Xia XQ; Li YQ; Sun YY; Jia YM; Wang J; Xue HQ; Gao GS; Wang XZ; Zhang XM; Guo XJ
    Breast Cancer Res Treat; 2022 Nov; 196(1):45-56. PubMed ID: 36056297
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PD-L1-Positive High-Grade Triple-Negative Breast Cancer Patients Respond Better to Standard Neoadjuvant Treatment-A Retrospective Study of PD-L1 Expression in Relation to Different Clinicopathological Parameters.
    Stanowska O; Kuczkiewicz-Siemion O; Dębowska M; Olszewski WP; Jagiełło-Gruszfeld A; Tysarowski A; Prochorec-Sobieszek M
    J Clin Med; 2022 Sep; 11(19):. PubMed ID: 36233396
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Phase II Clinical Trial of Pembrolizumab and Enobosarm in Patients with Androgen Receptor-Positive Metastatic Triple-Negative Breast Cancer.
    Yuan Y; Lee JS; Yost SE; Frankel PH; Ruel C; Egelston CA; Guo W; Gillece JD; Folkerts M; Reining L; Highlander SK; Robinson K; Padam S; Martinez N; Tang A; Schmolze D; Waisman J; Sedrak M; Lee PP; Mortimer J
    Oncologist; 2021 Feb; 26(2):99-e217. PubMed ID: 33141975
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Programmed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients.
    Botti G; Collina F; Scognamiglio G; Rao F; Peluso V; De Cecio R; Piezzo M; Landi G; De Laurentiis M; Cantile M; Di Bonito M
    Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28230773
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic significance of androgen receptor expression in HER2-positive and triple-negative breast cancer.
    Kucukzeybek BB; Bayoglu IV; Kucukzeybek Y; Yıldız Y; Oflazoglu U; Atahan MK; Taskaynatan H; Alacacioglu A; Yigit S; Tarhan MO
    Pol J Pathol; 2018; 69(2):157-168. PubMed ID: 30351863
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A high CD8 to FOXP3 ratio in the tumor stroma and expression of PTEN in tumor cells are associated with improved survival in non-metastatic triple-negative breast carcinoma.
    Tavares MC; Sampaio CD; Lima GE; Andrade VP; Gonçalves DG; Macedo MP; Cordeiro de Lima VC
    BMC Cancer; 2021 Aug; 21(1):901. PubMed ID: 34362334
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lack of Androgen Receptor Expression Selects for Basal-Like Phenotype and Is a Predictor of Poor Clinical Outcome in Non-Metastatic Triple Negative Breast Cancer.
    Riaz N; Idress R; Habib S; Lalani EN
    Front Oncol; 2020; 10():1083. PubMed ID: 32850312
    [No Abstract]   [Full Text] [Related]  

  • 36. The prognostic significance of combined androgen receptor, E-Cadherin, Ki67 and CK5/6 expression in patients with triple negative breast cancer.
    Adamo B; Ricciardi GRR; Ieni A; Franchina T; Fazzari C; Sanò MV; Angelico G; Michele C; Tuccari G; Adamo V
    Oncotarget; 2017 Sep; 8(44):76974-76986. PubMed ID: 29100362
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression of PD-L1 and BRCA1 in Triple-Negative Breast Cancer Patients and Relationship with Clinicopathological Characteristics.
    Huang X; Wang X; Qian H; Jin X; Jiang G
    Evid Based Complement Alternat Med; 2021; 2021():5314016. PubMed ID: 34721634
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The expression and clinical significance of the androgen receptor and E-cadherin in triple-negative breast cancer.
    Tang D; Xu S; Zhang Q; Zhao W
    Med Oncol; 2012 Jun; 29(2):526-33. PubMed ID: 21519872
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association between androgen receptor status and prognosis in triple negative breast cancer.
    Sunar V; T Dogan H; Sarici F; Ates O; Akin S; Baspinar B; Aksoy S; Altundag K
    J BUON; 2018; 23(5):1325-1330. PubMed ID: 30570854
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combining Analysis of Tumor-infiltrating Lymphocytes (TIL) and PD-L1 Refined the Prognostication of Breast Cancer Subtypes.
    Ni Y; Tsang JY; Shao Y; Poon IK; Tam F; Shea KH; Tse GM
    Oncologist; 2022 Apr; 27(4):e313-e327. PubMed ID: 35380716
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.